Biohaven Appoints Vlad Coric M.D. as Chief Executive Officer

NEW HAVEN, Conn., Nov. 19, 2015 (GLOBE NEWSWIRE) — via PRWEB – The Board of Directors of Biohaven Pharmaceutical Holding Company Limited (d/b/a Biohaven) is pleased to announce the election of Vlad Coric, M.D. as Chief Executive Officer. Dr. Coric has had a distinguished academic and pharmaceutical career with more than 15 years of drug discovery and clinical development experience at Yale University School of Medicine and Bristol-Myers Squibb.Within the pharmaceutical industry, Dr. Coric has worked across therapeutic areas including neuroscience, oncology, immuno-oncology and virology. He has been involved in multiple research and development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). Most recently at Bristol-Myers Squibb, Dr. Coric was the Neuro-Oncology…


Link to Full Article: Biohaven Appoints Vlad Coric M.D. as Chief Executive Officer

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!